Locust Walk views RNA therapeutics in 5 key pillars:

• RNA Translation Inhibition
• Protein Expression
• RNA-Targeting Small Molecules
• RNA Editing
• RNA-Mediated Protein and Transcriptome Regulation

While these key pillars are not exhaustive and approaches may overlap between multiple, these areas have seen a great deal of innovation and attention from strategics and investors as a result.

Strategic partners have had an appetite to collaborate with promising discovery stage RNA therapeutics companies, evidenced by over 25 licensing and M&A transactions since 2018.

The private financing landscape reflects a similar enthusiasm for the space, with investors providing nearly 3x step-ups in valuation for companies able to demonstrate proof of principle.

Overall, the RNA therapeutics landscape represents a vertical with exciting potential, with upcoming data readouts from the leaders in the space critical to near term growth prospects.

We invite you to read our report and welcome the opportunity to discuss its contents with you.